BIO, PhRMA and US Chamber of Commerce express fear of UN High-Level Panel on Access to Medicines in letter to Senator Hatch

In a sternly worded letter dated 18 February 2016, the Biotechnology Innovation Organization (BIO), the National Association of Manufacturers (NAM), the National Foreign Trade Council (NFTC), the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. Chamber of Commerce (the Chamber) and the United States Council for International Business (USCIB) wrote Senator Orrin Hatch (Republican – Utah) expressing serious reservations with the United Nations High-Level Panel on Access to Medicines (UN HLP). Continue Reading

Uncategorized

11 Groups Urge NIH to Lower Price of Xtandi, NIH/Army-Funded Prostate Cancer Drug With $129k/Year Price Tag

CONTACT:
Zack Struver
zack.struver@keionline.org
+1 (914) 582-1428

FOR RELEASE: MARCH 21, 2016

Non-Profit Groups Urge Obama Administration, NIH to Lower Price of Government-Funded, $129,000 Per Year Prostate Cancer Drug
The groups asked the National Institutes of Health to “take this opportunity to act” to lower the price of the prostate cancer drug Xtandi and show leadership on deterring discriminatory pricing practices.

Continue Reading

Uncategorized

Briefing on Beijing Treaty on Audiovisual Performers

On Monday, March 7, 2016, from 1:45 P.M. to 2:45 P.M., the US Patent and Trademark Office (USPTO) met with invited stakeholders in a briefing at the White House on the Beijing Treaty on Audiovisual Performances and the implementation package that was sent to Congress on February 29, 2016. The package was submitted for review to the Senate Foreign Relations and Judiciary Committees.

Continue Reading

Uncategorized

Congressman Doggett Voices Support for KEI/UACT Petition to NIH on Xtandi

On Monday, March 7, 2016, Congressman Lloyd Doggett, D-Texas, issued a statement in support of the recent Knowledge Ecology International (KEI) and Union for Affordable Cancer Treatment (UACT) request that the National Institutes of Health (NIH) authorize the generic production of an expensive prostate cancer drug in order to curb an excessive and discriminatory price in the United States.

Continue Reading

Uncategorized

TRIPS Council March 2016: India reiterates support for de-linkage and references UN High Level Panel on Access to Medicines

In early March 2016, the World Trade Organization’s (WTO) TRIPS Council discussed “Intellectual Property and Innovation: Education and Diffusion”. The following delegations co-sponsored discussion of this item on Education and Diffusion – Australia, European Union, Switzerland, United States, Japan, Singapore, Peru, Russian Federation, Chinese Taipei and Hong Kong China.

Continue Reading

Uncategorized